Iradimed Corp (IRMD)
NASDAQ:IRMD
Top Page
Iradimed
(NASDAQ:IRMD)
Select Model
Select Model
Rating:76Outperform
Price Target:
$112.00
▲(46.56% Upside)
Action:ReiteratedDate:03/07/26
IRMD scores well primarily on strong financial performance (high and improving profitability, near debt-free balance sheet, and positive free cash flow). The earnings call adds support with upbeat guidance tied to the 3870 pump and a targeted 2026 acceleration, though execution/transition and geographic concentration risks remain. Offsetting these positives are a demanding valuation (P/E ~55) and a mixed near-term technical picture with the stock below its 20/50-day averages.
Positive Factors
Sustained high profitability
Consistently high gross and operating margins and expanding net margins indicate durable pricing power and tight cost control in a niche MRI-compatible devices market. This margin profile supports sustained cash generation and reinvestment capacity, making core profitability resilient over 2–6 months.
Negative Factors
High U.S. revenue concentration
Heavy reliance on the U.S. market exposes results to domestic hospital purchasing cycles, reimbursement changes, or demand shifts. Delayed international regulatory approvals limit geographic diversification, leaving revenue and growth sensitive to U.S. execution over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained high profitability
Consistently high gross and operating margins and expanding net margins indicate durable pricing power and tight cost control in a niche MRI-compatible devices market. This margin profile supports sustained cash generation and reinvestment capacity, making core profitability resilient over 2–6 months.
Read all positive factors
Iradimed (IRMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.20B
Dividend Yield1.22%
Average Volume (3M)87.37K
Price to Earnings (P/E)55.1
Beta (1Y)0.68
Revenue Growth12.91%
EPS Growth13.24%
CountryUS
Employees160
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.54
Shares Outstanding12,782,566
10 Day Avg. Volume105,223
30 Day Avg. Volume87,367
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue13.66
Enterprise Value/Gross Profit17.80
Enterprise Value/Ebitda39.56
Forecast
1Y Price Target
$118.67Price Target Upside55.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.08
Revenue Forecast (FY)$91.92M
Iradimed Business Overview & Revenue Model
Company Description
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intr...
How the Company Makes Money
Iradimed generates revenue primarily through the sale of its MRI-compatible products, including infusion pumps and monitoring systems. The company has established a recurring revenue stream through the sale of disposables and accessories that are ...
Iradimed Key Performance Indicators (KPIs)
Iradimed Earnings Call Summary
Earnings Call Date:Feb 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 24, 2026
Earnings Call Sentiment Positive
The call was largely positive: management reported broad-based, double-digit revenue growth, improved EPS, strong gross margins, healthy cash balances, and encouraging early demand and ASP uplift potential from the new 3870 pump. Key risks center on the operational transition from the legacy 3860 to the 3870 (inventory management and subscale margin pressure early in the ramp), geographic concentration in the U.S., and delayed international regulatory clearances. Provided execution on manufacturing ramp, sales bookings, and hospital adoption proceeds as planned, the company is positioned for meaningful revenue acceleration in 2026; however, near-term operational and timing risks merit monitoring.Positive Updates
Record Revenues and Growth Pace
Q4 2025 revenue of $22.7M, a 17% increase YoY; fiscal 2025 revenue of $83.8M, up 14% YoY. This marks the company's 18th consecutive quarter of record revenue.
Negative Updates
Inventory and Transition Risk from 3860 to 3870
Management noted the need to carefully manage 3860 inventory and the transition to 3870; Q4 inventory increased as 3870 components were brought in, and the transition is expected to be a key operational challenge in Q2 2026.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Revenues and Growth Pace
Q4 2025 revenue of $22.7M, a 17% increase YoY; fiscal 2025 revenue of $83.8M, up 14% YoY. This marks the company's 18th consecutive quarter of record revenue.
Read all positive updates
Company Guidance
Management guided that the new 3870 pump should drive meaningful upside, with deal ASPs expected to be 10–14% higher and a plan to add ~1,000 replacement channels/year (targeting sales north of 2,000 3870 pump channels annually in the U.S., up from the current ~1,100 channels sold domestically), targeting the ~6,400 U.S. 5+-year‑old 3860/3861 channels and aiming for an approximate $50M pump revenue run rate, and with disposables, maintenance, international sales and MRI monitoring they expect a $100M+ company revenue run rate in 2026; operationally they shipped an initial 23 units in December (with clinical support through Feb/early‑Mar), plan a general launch in April with ~100–130 3870 channel shipments, expect bookings to build in Q2 and ramp in H2 while maintaining Q1–H1 revenue from MRI monitoring and 3860 backlog, and anticipate CE mark by year‑end and Japan clearance the following summer.Iradimed Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
79
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.81M | 73.24M | 65.56M | 53.30M | 41.81M |
| Gross Profit | 64.32M | 56.35M | 50.16M | 41.28M | 32.05M |
| EBITDA | 28.53M | 22.78M | 20.80M | 16.30M | 11.22M |
| Net Income | 22.48M | 19.23M | 17.19M | 12.83M | 9.33M |
Balance Sheet | |||||
| Total Assets | 108.78M | 98.33M | 92.16M | 85.51M | 82.88M |
| Cash, Cash Equivalents and Short-Term Investments | 51.16M | 52.23M | 49.76M | 57.96M | 62.50M |
| Total Debt | 0.00 | 154.69K | 2.04M | 2.21M | 2.48M |
| Total Liabilities | 14.16M | 11.51M | 20.74M | 11.84M | 10.71M |
| Stockholders Equity | 94.62M | 86.82M | 71.42M | 73.67M | 72.17M |
Cash Flow | |||||
| Free Cash Flow | 17.18M | 17.62M | 5.46M | 8.17M | 10.52M |
| Operating Cash Flow | 24.95M | 25.62M | 13.47M | 10.04M | 11.26M |
| Investing Cash Flow | -8.42M | -8.82M | -8.01M | -1.37M | 648.24K |
| Financing Cash Flow | -17.60M | -14.34M | -13.66M | -12.71M | 24.43K |
Iradimed Technical Analysis
Negative
76.42
Price Trends
99.09
Negative
97.64
Negative
83.70
Positive
Market Momentum
-1.66
Positive
39.76
Neutral
27.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Negative. The current price of 76.42 is below the 20-day moving average (MA) of 97.32, below the 50-day MA of 99.09, and below the 200-day MA of 83.70, indicating a neutral trend. The MACD of -1.66 indicates Positive momentum. The RSI at 39.76 is Neutral, neither overbought nor oversold. The STOCH value of 27.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRMD.
Iradimed Risk Analysis
Iradimed disclosed 36 risk factors in its most recent earnings report. Iradimed reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Iradimed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.20B | 55.05 | 23.83% | 1.22% | 12.91% | 13.24% | |
65 Neutral | $783.32M | 21.81 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $1.74B | -95.98 | -13.44% | ― | 18.72% | 85.77% | |
56 Neutral | $618.31M | -45.38 | -12.91% | ― | 23.27% | 43.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $507.83M | -6.56 | -20.38% | ― | 4.31% | 3.26% | |
47 Neutral | $798.08M | -1.85 | -39.90% | ― | 4.99% | -7151.40% |
* Healthcare Sector Average
IRMD
Iradimed
93.56
42.36
82.73%
IART
Integra Lifesciences
11.06
-4.69
-29.78%
OFIX
Orthofix Medical
12.72
-0.24
-1.85%
AXGN
AxoGen
34.46
18.88
121.18%
SIBN
SI-Bone
14.43
1.10
8.25%
BVS
Bioventus
9.91
2.13
27.38%
Iradimed Corporate Events
DividendsFinancial Disclosures
Iradimed Declares Special Cash Dividend for Shareholders
Positive
Dec 8, 2025
On December 5, 2025, IRADIMED CORPORATION’s Board of Directors declared a special cash dividend of $0.50 per share, payable on December 30, 2025, to shareholders of record as of December 17, 2025. This decision reflects the company’s s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.